carbon monoxide has been researched along with Sclerosis, Systemic in 71 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
| Excerpt | Relevance | Reference |
|---|---|---|
| "1% during follow-up, and it was significantly associated to digital ulcers, interstitial lung disease, reduction of diffusion lung of carbon monoxide <75%, teleangectasias and melanodermia, while sicca syndrome and arthralgias were associated to normal/nonspecific pattern." | 3.81 | Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications. ( Campomori, F; Colaci, M; Ferri, C; Ghizzoni, C; Giuggioli, D; Manfredi, A; Sebastiani, M, 2015) |
| "In systemic sclerosis (SSc), impaired diffusing capacity for carbon monoxide (DLCO) can indicate interstitial lung disease (ILD), pulmonary hypertension (PH), and/or other disease manifestations, including anemia." | 3.79 | Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. ( Assayag, D; Baron, M; Caron, M; Fox, BD; Gaudreau-Taillefer, R; Hirsch, A; Hudson, M; Rudski, L; Steele, R; Tatibouet, S, 2013) |
| "To determine whether there are factors, such as the diffusing capacity for carbon monoxide (DLCO) or pulmonary artery pressure (PAP) on echocardiogram, that can predict the development of pulmonary hypertension (PHT) in patients with limited scleroderma." | 3.72 | Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. ( Medsger, TA; Steen, V, 2003) |
| "Patients with SSc meeting the ACR/EULAR systemic sclerosis classification criteria with diffuse cutaneous SSc (dcSSc) subset per LeRoy criteria, and a disease duration of less than or equal to 18 months will be randomized to placebo or riociguat 0." | 2.84 | RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. ( Allanore, Y; de Oliveira Pena, J; Denton, C; Distler, O; Khanna, D; Matucci-Cerinic, M; Pope, J, 2017) |
| "Extent of systemic sclerosis (SSc)-related interstitial lung disease (ILD) assessed from thoracic high-resolution CT (HRCT) predicts disease course, mortality and treatment response." | 2.82 | Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. ( Clements, P; Elashoff, R; Furst, D; Goldin, J; Khanna, D; Kim, HJ; Kleerup, E; Roth, MD; Tashkin, DP; Tseng, CH; Volkmann, ER, 2016) |
| "Currently, therapy for interstitial lung disease in patients with systemic sclerosis is unsatisfactory." | 2.74 | High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. ( Bambery, P; Sharma, A; Sharma, S; Suryanaryana, BS; Wanchu, A, 2009) |
| "Pulmonary fibrosis in systemic sclerosis (SSc) is thought to be the consequence of interstitial inflammation." | 2.73 | Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. ( Beretta, L; Caronni, M; Origgi, L; Ponti, A; Raimondi, M; Scorza, R; Viscuso, T, 2007) |
| "Nineteen patients with systemic sclerosis (15 women and four men, aged 25-67 years, mean disease duration 5 years and 9 months) were included in this study." | 2.72 | Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy. ( Damjanov, N; Ostojic, P, 2006) |
| "Patients with systemic sclerosis (SSc) do not exhibit a normal increase in the diffusing capacity for carbon monoxide (DLCO) on assuming the supine position." | 2.67 | Failure of vasoldilator infusion to alter pulmonary diffusing capacity in systemic sclerosis. ( Dole, WP; Thurm, CA; Wigley, FM; Wise, RA, 1991) |
| "Hearing loss was detected in 23." | 1.72 | Audiological involvement in patients with systemic sclerosis. ( Arslan, M; Meco, C; Okatan, E; Tokgoz Yilmaz, S; Turan, K; Turgay, M; Yayla, ME, 2022) |
| "A retrospective observational study was performed on 68 SSc patients treated with 5-6 infusions of iloprost per month for 6 hours per day at a dosage of 0." | 1.72 | Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study. ( Amato, G; Bellofiore, S; Benenati, A; Dal Bosco, Y; Foti, R; Gagliano, C; Piazza, R; Visalli, E, 2022) |
| "Of the entire cohort (n = 243), systemic sclerosis (SSc)-associated ILD (n = 88, 36%), interstitial pneumonia with autoimmune features (IPAF, n = 56, 23%), rheumatoid arthritis (RA)-associated ILD (n = 42, 17%), and idiopathic inflammatory myopathy (IIM)-associated ILD (n = 26, 11%) were the most common phenotypes." | 1.51 | Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. ( Chartrand, S; Fischer, A; Lee, JS; Stanchev, L; Swigris, JJ, 2019) |
| "Pulmonary emphysema combined with systemic sclerosis (SSc)-associated interstitial lung disease (ILD) occurs more often in smokers but also in never-smokers." | 1.48 | Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy? ( Baba, T; Ikeda, S; Iso, S; Iwasawa, T; Kitamura, H; Kuwano, K; Ogura, T; Okudela, K; Sekine, A; Takemura, T; Yamakawa, H; Yamanaka, Y, 2018) |
| "Systemic sclerosis-related interstitial lung disease (SSc-ILD) is the leading cause of death in SSc." | 1.46 | Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. ( Béhal, H; Duhamel, A; Faivre, JB; Hachulla, AL; Hachulla, E; Hatron, PY; Lambert, M; Launay, D; Le Gouellec, N; Matran, R; Morell-Dubois, S; Perez, T; Remy-Jardin, M; Sobanski, V, 2017) |
| "More than 80% of patients with systemic sclerosis (SSc) develop lung involvement, most commonly interstitial pneumonia (IP)." | 1.38 | The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. ( Carns, M; Fingerlin, TE; Hinchcliff, ME; Murphy, E; Peljto, AL; Podlusky, S; Schwartz, DA; Schwarz, M; Steele, MP; Varga, J, 2012) |
| "Pulmonary hypertension (PH) complicating systemic sclerosis (SSc)-related interstitial lung disease (ILD) is usually associated with a poor prognosis." | 1.37 | Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. ( Allanore, Y; Berezne, A; Bletry, O; Clerson, P; Cottin, V; Couderc, LJ; Hachulla, E; Hatron, PY; Humbert, M; Launay, D; Le Pavec, J; Mouthon, L; Yaici, A, 2011) |
| "We investigated in systemic sclerosis (SSc) patients the T cell homeostasis and its relationship with the clinical course of the disease." | 1.36 | Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. ( Gambardella, L; Giammarioli, AM; Giovannetti, A; Malorni, W; Maselli, A; Palange, P; Paoletti, P; Pierdominici, M; Pisarri, S; Renzi, C; Rosato, E; Salsano, F, 2010) |
| "Eight patients developed PAH, 29 had disease progression, and 10 died during a median followup of 29 months." | 1.35 | High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. ( Allanore, Y; Avouac, J; Borderie, D; Ekindjian, OG; Guillevin, L; Hachulla, E; Kahan, A; Meune, C; Meyer, O; Mouthon, L; Weber, S; Zerkak, D, 2008) |
| "Pulmonary fibrosis in systemic sclerosis (SSc) involves inflammatory processes in the lower respiratory tract." | 1.35 | Cytokine concentrations in exhaled breath condensates in systemic sclerosis. ( Boulenguez, C; Dessaint, JP; Edmé, JL; Grutzmacher, C; Hachulla, E; Hatron, PY; Labalette, M; Launay, D; Matran, R; Neviere, R; Sobaszek, A; Tellart, AS, 2008) |
| "Age and the presence of interstitial lung disease (ILD) were associated with more frequent occurrence of TG > 23 and > 33 mmHg initially and at follow-up, but were not associated with progression rate." | 1.33 | Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. ( Akesson, A; Ekman, R; Eskilsson, J; Hesselstrand, R; Isaksson, A; Ohlin, AK; Scheja, A, 2005) |
| "A total of 137 (52 with and 85 without pulmonary fibrosis) had echocardiography and lung function tests within 3 months of their definitive invasive study." | 1.32 | Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. ( Black, CM; Coghlan, JG; Davar, J; Du Bois, RM; Knight, C; Mukerjee, D; St George, D; Wells, AU, 2004) |
| "The presence of lung inflammation identifies patients with scleroderma who are more likely to have worsening lung function." | 1.31 | Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. ( Moore, WC; White, B; Wigley, FM; Wise, RA; Xiao, HQ, 2000) |
| "Pulmonary disease is responsible for considerable morbidity and mortality in systemic sclerosis (SSc)." | 1.29 | Early pulmonary disease in systemic sclerosis: a comparison between carbon monoxide transfer factor and static lung compliance. ( Akesson, A; Scheja, A; Wollheim, FA; Wollmer, P, 1993) |
| "Pulmonary hypertension was strongly associated with an initial DLCO of less than 55% of predicted normal and a FVC (% predicted)/DLCO (% predicted) ratio of greater than 1." | 1.28 | Isolated diffusing capacity reduction in systemic sclerosis. ( Conte, C; Graham, G; Medsger, TA; Owens, G; Steen, VD, 1992) |
| "Treatment with nifedipine did not significantly change any of the pulmonary function values, except for the carbon monoxide diffusing capacity (DLCO)." | 1.28 | Diffusing capacity of the lung and nifedipine in systemic sclerosis. ( Georgiakodis, F; Kyriakidis, M; Papazoglou, S; Sfikakis, P; Sfikakis, PP; Toutouzas, P; Vergos, C, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (8.45) | 18.7374 |
| 1990's | 7 (9.86) | 18.2507 |
| 2000's | 15 (21.13) | 29.6817 |
| 2010's | 32 (45.07) | 24.3611 |
| 2020's | 11 (15.49) | 2.80 |
| Authors | Studies |
|---|---|
| Turan, K | 1 |
| Yayla, ME | 1 |
| Arslan, M | 1 |
| Tokgoz Yilmaz, S | 1 |
| Okatan, E | 1 |
| Turgay, M | 1 |
| Meco, C | 1 |
| Yeo, J | 1 |
| Kim, JY | 1 |
| Kim, MH | 1 |
| Park, JW | 1 |
| Park, JK | 1 |
| Lee, EB | 2 |
| Favoino, E | 1 |
| Catacchio, G | 1 |
| Mininni, A | 1 |
| Ruscitti, P | 1 |
| Riccieri, V | 1 |
| Liakouli, V | 1 |
| Corrado, A | 1 |
| Navarini, L | 1 |
| Ciccia, F | 1 |
| Cipriani, P | 1 |
| Cantatore, FP | 1 |
| Valesini, G | 1 |
| Giacomelli, R | 1 |
| Perosa, F | 1 |
| Ibrahim, NH | 1 |
| Fawzy, IM | 1 |
| Gouda, TM | 1 |
| El Sayed, RAH | 1 |
| Morsi, MH | 1 |
| Sabry, ASM | 1 |
| Hashaad, NI | 1 |
| Nihtyanova, SI | 1 |
| Schreiber, BE | 1 |
| Ong, VH | 1 |
| Wells, AU | 3 |
| Coghlan, JG | 2 |
| Denton, CP | 2 |
| Wajda, A | 1 |
| Walczyk, M | 1 |
| Dudek, E | 1 |
| Stypińska, B | 1 |
| Lewandowska, A | 1 |
| Romanowska-Próchnicka, K | 1 |
| Chojnowski, M | 1 |
| Olesińska, M | 1 |
| Paradowska-Gorycka, A | 1 |
| Foti, R | 6 |
| Amato, G | 3 |
| Benenati, A | 3 |
| Dal Bosco, Y | 3 |
| Piazza, R | 3 |
| Gagliano, C | 3 |
| Bellofiore, S | 3 |
| Visalli, E | 3 |
| Chartrand, S | 1 |
| Lee, JS | 1 |
| Swigris, JJ | 1 |
| Stanchev, L | 1 |
| Fischer, A | 1 |
| Santaniello, A | 1 |
| Casella, R | 1 |
| Vicenzi, M | 1 |
| Rota, I | 1 |
| Montanelli, G | 1 |
| De Santis, M | 1 |
| Bellocchi, C | 1 |
| Lombardi, F | 1 |
| Beretta, L | 2 |
| Ciaffi, J | 1 |
| van Leeuwen, NM | 1 |
| Liem, SIE | 1 |
| Ninaber, MK | 1 |
| Huizinga, TWJ | 1 |
| de Vries-Bouwstra, JK | 1 |
| Distler, O | 2 |
| Assassi, S | 1 |
| Cottin, V | 2 |
| Cutolo, M | 1 |
| Danoff, SK | 1 |
| Distler, JHW | 2 |
| Hoffmann-Vold, AM | 1 |
| Johnson, SR | 1 |
| Müller Ladner, U | 1 |
| Smith, V | 1 |
| Volkmann, ER | 3 |
| Maher, TM | 1 |
| Štorkánová, H | 1 |
| Oreská, S | 1 |
| Špiritović, M | 1 |
| Heřmánková, B | 1 |
| Bubová, K | 1 |
| Komarc, M | 1 |
| Pavelka, K | 1 |
| Vencovský, J | 1 |
| Šenolt, L | 1 |
| Bečvář, R | 1 |
| Tomčík, M | 1 |
| Le Gouellec, N | 1 |
| Duhamel, A | 1 |
| Perez, T | 3 |
| Hachulla, AL | 1 |
| Sobanski, V | 2 |
| Faivre, JB | 1 |
| Morell-Dubois, S | 2 |
| Lambert, M | 2 |
| Hatron, PY | 4 |
| Hachulla, E | 5 |
| Béhal, H | 1 |
| Matran, R | 2 |
| Launay, D | 5 |
| Remy-Jardin, M | 2 |
| Degano, B | 2 |
| Soumagne, T | 1 |
| Delaye, T | 1 |
| Berger, P | 1 |
| Guillien, A | 1 |
| Pellegrin, JL | 1 |
| Magy-Bertrand, N | 2 |
| Agard, C | 1 |
| Tiev, KP | 2 |
| Hua-Huy, T | 2 |
| Tardiff, C | 1 |
| Diaz, V | 1 |
| Chambellan, A | 1 |
| Dinh-Xuan, AT | 3 |
| Borghini, A | 1 |
| Poscia, A | 1 |
| Bosello, S | 1 |
| Teleman, AA | 1 |
| Bocci, M | 1 |
| Iodice, L | 1 |
| Ferraccioli, G | 1 |
| La Milìa, DI | 1 |
| Moscato, U | 1 |
| Yamakawa, H | 1 |
| Takemura, T | 1 |
| Iwasawa, T | 1 |
| Yamanaka, Y | 1 |
| Ikeda, S | 1 |
| Sekine, A | 1 |
| Kitamura, H | 1 |
| Baba, T | 1 |
| Iso, S | 1 |
| Okudela, K | 1 |
| Kuwano, K | 1 |
| Ogura, T | 1 |
| Caetano, J | 1 |
| Paula, FS | 1 |
| Amaral, M | 1 |
| Oliveira, S | 1 |
| Alves, JD | 1 |
| Pavlov-Dolijanovic, S | 1 |
| Vujasinovic Stupar, N | 1 |
| Zugic, V | 1 |
| Ostojic, P | 2 |
| Zekovic, A | 1 |
| Zivanovic Radnic, T | 1 |
| Jeremic, I | 1 |
| Tadic, I | 1 |
| Corzo, P | 1 |
| Pros, A | 1 |
| Martinez-Llorens, J | 1 |
| Molina, L | 1 |
| Ling, SF | 1 |
| Balcells, E | 1 |
| Tashkin, DP | 3 |
| Sim, M | 1 |
| Li, N | 1 |
| Goldmuntz, E | 1 |
| Keyes-Elstein, L | 1 |
| Pinckney, A | 1 |
| Furst, DE | 2 |
| Clements, PJ | 2 |
| Khanna, D | 4 |
| Steen, V | 2 |
| Schraufnagel, DE | 1 |
| Arami, S | 1 |
| Hsu, V | 1 |
| Roth, MD | 3 |
| Elashoff, RM | 1 |
| Sullivan, KM | 1 |
| Abdulle, AE | 1 |
| van Goor, H | 1 |
| Mulder, DJ | 1 |
| Radtke, T | 1 |
| Dressel, H | 1 |
| Ninagawa, K | 1 |
| Kato, M | 1 |
| Nakamura, H | 1 |
| Abe, N | 1 |
| Kono, M | 1 |
| Fujieda, Y | 1 |
| Oku, K | 1 |
| Yasuda, S | 1 |
| Ohira, H | 1 |
| Tsujino, I | 1 |
| Atsumi, T | 1 |
| Hudson, M | 1 |
| Assayag, D | 1 |
| Caron, M | 1 |
| Fox, BD | 1 |
| Hirsch, A | 1 |
| Steele, R | 1 |
| Gaudreau-Taillefer, R | 1 |
| Tatibouet, S | 1 |
| Rudski, L | 1 |
| Baron, M | 1 |
| Someya, F | 1 |
| Mugii, N | 1 |
| Hasegawa, M | 2 |
| Yahata, T | 1 |
| Nakagawa, T | 1 |
| Sivova, N | 1 |
| Wémeau-Stervinou, L | 1 |
| De Groote, P | 1 |
| Denis, G | 1 |
| Lamblin, N | 1 |
| Fertin, M | 1 |
| Lefevre, G | 1 |
| Le Rouzic, O | 1 |
| Wallaert, B | 1 |
| Głodkowska-Mrówka, E | 1 |
| Górska, E | 1 |
| Ciurzyński, M | 1 |
| Stelmaszczyk-Emmel, A | 1 |
| Bienias, P | 1 |
| Irzyk, K | 1 |
| Siwicka, M | 1 |
| Lipińska, A | 1 |
| Ciepiela, O | 1 |
| Pruszczyk, P | 1 |
| Demkow, U | 1 |
| Tseng, CH | 1 |
| Kim, HJ | 1 |
| Goldin, J | 1 |
| Clements, P | 1 |
| Furst, D | 1 |
| Kleerup, E | 1 |
| Elashoff, R | 2 |
| Ghizzoni, C | 1 |
| Sebastiani, M | 2 |
| Manfredi, A | 2 |
| Campomori, F | 1 |
| Colaci, M | 2 |
| Giuggioli, D | 2 |
| Ferri, C | 2 |
| Adrovic, A | 1 |
| Oztunc, F | 1 |
| Barut, K | 1 |
| Koka, A | 1 |
| Gojak, R | 1 |
| Sahin, S | 1 |
| Demir, T | 1 |
| Kasapcopur, O | 1 |
| Legnani, D | 1 |
| Rizzi, M | 1 |
| Sarzi-Puttini, P | 1 |
| Cristiano, A | 1 |
| La Spina, T | 1 |
| Frassanito, F | 1 |
| Airoldi, A | 1 |
| Atzeni, F | 1 |
| Lumetti, F | 1 |
| Luppi, F | 1 |
| Cerri, S | 1 |
| van Bon, L | 1 |
| Cossu, M | 1 |
| Scharstuhl, A | 1 |
| Pennings, BW | 1 |
| Vonk, MC | 1 |
| Vreman, HJ | 1 |
| Lafyatis, RL | 1 |
| van den Berg, W | 1 |
| Wagener, FA | 1 |
| Radstake, TR | 1 |
| Giusti, L | 1 |
| Sernissi, F | 1 |
| Donadio, E | 1 |
| Ciregia, F | 1 |
| Giacomelli, C | 1 |
| Giannaccini, G | 1 |
| Mazzoni, MR | 1 |
| Lucacchini, A | 1 |
| Bazzichi, L | 1 |
| Pope, J | 1 |
| Denton, C | 1 |
| Allanore, Y | 3 |
| Matucci-Cerinic, M | 1 |
| de Oliveira Pena, J | 1 |
| Wanchu, A | 1 |
| Suryanaryana, BS | 1 |
| Sharma, S | 1 |
| Sharma, A | 1 |
| Bambery, P | 1 |
| Giovannetti, A | 1 |
| Rosato, E | 1 |
| Renzi, C | 1 |
| Maselli, A | 1 |
| Gambardella, L | 1 |
| Giammarioli, AM | 1 |
| Palange, P | 1 |
| Paoletti, P | 1 |
| Pisarri, S | 1 |
| Salsano, F | 1 |
| Malorni, W | 1 |
| Pierdominici, M | 1 |
| Hesselstrand, R | 2 |
| Wildt, M | 1 |
| Ekmehag, B | 1 |
| Wuttge, DM | 1 |
| Scheja, A | 3 |
| Celebi Sözener, Z | 1 |
| Karabıyıkoğlu, G | 1 |
| Düzgün, N | 1 |
| Michalska-Jakubus, M | 1 |
| Kowal-Bielecka, O | 1 |
| Chodorowska, G | 1 |
| Bielecki, M | 1 |
| Krasowska, D | 1 |
| Humbert, M | 1 |
| Berezne, A | 1 |
| Couderc, LJ | 1 |
| Bletry, O | 1 |
| Yaici, A | 1 |
| Mouthon, L | 3 |
| Le Pavec, J | 1 |
| Clerson, P | 1 |
| Trad, S | 1 |
| Huong, du LT | 1 |
| Frances, C | 1 |
| Wechsler, B | 1 |
| Cacoub, P | 1 |
| Costedoat, N | 1 |
| Haroche, J | 1 |
| Piette, JC | 1 |
| Hanslik, T | 1 |
| Amoura, Z | 1 |
| Pernot, J | 1 |
| Puzenat, E | 1 |
| Manzoni, P | 1 |
| Gondouin, A | 1 |
| Bourdin, H | 1 |
| Simon-Rigaud, ML | 1 |
| Regnard, J | 1 |
| Peljto, AL | 1 |
| Steele, MP | 1 |
| Fingerlin, TE | 1 |
| Hinchcliff, ME | 1 |
| Murphy, E | 1 |
| Podlusky, S | 1 |
| Carns, M | 1 |
| Schwarz, M | 1 |
| Varga, J | 2 |
| Schwartz, DA | 1 |
| Matsukawa, Y | 1 |
| Saito, O | 1 |
| Aoki, M | 1 |
| Abe, M | 1 |
| Nishinarita, S | 1 |
| Sawada, S | 1 |
| Horie, T | 1 |
| Naruse, S | 1 |
| Hiranuma, M | 1 |
| Medsger, TA | 2 |
| POLLERI, A | 1 |
| CANEPA, F | 1 |
| DEGAETANI, G | 1 |
| Mukerjee, D | 1 |
| St George, D | 1 |
| Knight, C | 1 |
| Davar, J | 1 |
| Du Bois, RM | 2 |
| Black, CM | 2 |
| Ekman, R | 1 |
| Eskilsson, J | 1 |
| Isaksson, A | 1 |
| Ohlin, AK | 1 |
| Akesson, A | 2 |
| Chon, Y | 1 |
| Sterz, MG | 1 |
| Chung, J | 1 |
| FitzGerald, JD | 1 |
| Seibold, JR | 1 |
| Theodore, A | 1 |
| Wigley, FM | 4 |
| Silver, RM | 1 |
| Steen, VD | 2 |
| Mayes, MD | 1 |
| Connolly, MK | 1 |
| Fessler, BJ | 1 |
| Rothfield, NF | 1 |
| Mubarak, K | 1 |
| Molitor, J | 1 |
| Damjanov, N | 1 |
| Ogawa, F | 1 |
| Shimizu, K | 1 |
| Muroi, E | 1 |
| Hara, T | 1 |
| Takehara, K | 1 |
| Sato, S | 1 |
| Caronni, M | 1 |
| Raimondi, M | 1 |
| Ponti, A | 1 |
| Viscuso, T | 1 |
| Origgi, L | 1 |
| Scorza, R | 1 |
| Cabane, J | 1 |
| Aubourg, F | 1 |
| Kettaneh, A | 1 |
| Ziani, M | 1 |
| Duong-Quy, S | 1 |
| Fajac, I | 1 |
| Guillevin, L | 2 |
| Choi, HJ | 1 |
| Shin, YK | 1 |
| Lee, HJ | 1 |
| Kee, JY | 1 |
| Shin, DW | 1 |
| Lee, EY | 1 |
| Lee, YJ | 1 |
| Song, YW | 1 |
| Quadrelli, S | 1 |
| Ciallella, L | 1 |
| Catalán Pellet, AC | 1 |
| Molinari, L | 1 |
| Salvado, A | 1 |
| Auad, C | 1 |
| Spina, JC | 1 |
| Borderie, D | 1 |
| Avouac, J | 1 |
| Zerkak, D | 1 |
| Meune, C | 1 |
| Meyer, O | 1 |
| Ekindjian, OG | 1 |
| Weber, S | 1 |
| Kahan, A | 1 |
| Edmé, JL | 1 |
| Tellart, AS | 1 |
| Neviere, R | 1 |
| Grutzmacher, C | 1 |
| Boulenguez, C | 1 |
| Labalette, M | 1 |
| Dessaint, JP | 1 |
| Sobaszek, A | 1 |
| Randowa, D | 1 |
| Peters-Golden, M | 1 |
| Wise, RA | 3 |
| Hochberg, MC | 1 |
| Stevens, MB | 1 |
| Wollmer, P | 1 |
| Wollheim, FA | 1 |
| Dujić, Z | 1 |
| Eterović, D | 1 |
| Tocilj, J | 1 |
| Andjelinović, D | 1 |
| Hansell, DM | 1 |
| Rubens, MB | 1 |
| King, AD | 1 |
| Cramer, D | 1 |
| White, B | 1 |
| Moore, WC | 1 |
| Xiao, HQ | 1 |
| Salorinne, Y | 1 |
| Yamane, K | 1 |
| Miyauchi, T | 1 |
| Suzuki, N | 1 |
| Yuhara, T | 1 |
| Akama, T | 1 |
| Suzuki, H | 1 |
| Kashiwagi, H | 1 |
| Graham, G | 1 |
| Conte, C | 1 |
| Owens, G | 1 |
| Thurm, CA | 1 |
| Dole, WP | 1 |
| Sfikakis, PP | 1 |
| Kyriakidis, M | 1 |
| Vergos, C | 1 |
| Papazoglou, S | 1 |
| Georgiakodis, F | 1 |
| Toutouzas, P | 1 |
| Sfikakis, P | 1 |
| de Clerck, LS | 1 |
| Dequeker, J | 1 |
| Francx, L | 1 |
| Demedts, M | 1 |
| Colp, CR | 1 |
| Riker, J | 1 |
| Williams, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Utility of Breath-holding Test for Assessment of Pulmonary Disease Severity in Patients With Systemic Sclerosis[NCT04484948] | 120 participants (Actual) | Interventional | 2020-08-12 | Completed | |||
| Cyclophosphamide Versus Placebo in Scleroderma Lung Study[NCT00004563] | Phase 3 | 158 participants (Actual) | Interventional | 1999-08-31 | Completed | ||
| Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)[NCT00883129] | Phase 2 | 142 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)[NCT02283762] | Phase 2 | 121 participants (Actual) | Interventional | 2015-01-15 | Completed | ||
| Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension[NCT00377455] | Phase 2 | 5 participants (Actual) | Interventional | 2006-09-30 | Terminated (stopped due to Study was terminated due to inadequate enrolment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
diffusing capacity of the lungs for carbon monoxide (NCT00004563)
Timeframe: 12 months
| Intervention | % of predicted (Mean) |
|---|---|
| Cylophosphamide | 42.8 |
| Placebo | 44.3 |
The primary end point was the forced vital capacity (FVC, expressed as a percentage of the predicted value) at 12 months, after adjustment for the baseline FVC. (NCT00004563)
Timeframe: 12 months
| Intervention | % of predicted (Mean) |
|---|---|
| Cylophosphamide | 66.6 |
| Placebo | 65.6 |
expressed as a percentage of the predicted value (NCT00004563)
Timeframe: 12 months
| Intervention | % of predicted (Mean) |
|---|---|
| Cylophosphamide | 70.5 |
| Placebo | 64.7 |
Imaging of the whole lung (WL) is performed using a volumetric high resolution computerized tomography (HRCT) scan, which is then analyzed using a computer algorithm to determine the percentage of overall pixels exhibiting features characteristic for quantitative lung fibrosis (QLF). Higher percentages for QLF-WL therefore represent greater involvement by lung fibrosis. (NCT00883129)
Timeframe: Measured at baseline and Month 24
| Intervention | % of lung exhibiting QLF (Mean) | |
|---|---|---|
| Baseline | Month 24 | |
| Cyclophosphamide Arm | 8.91 | 8.48 |
| Mycophenolate Arm | 8.25 | 7.99 |
The primary outcome is the course over time from baseline to 24 months for the FVC %-predicted. The FVC %-predicted represents the adjusted volume of air (adjusted as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity) that can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of lung involvement and disease severity. (NCT00883129)
Timeframe: Measured at study Baseline and Months 3, 6, 12, 15, 18, 21, and 24
| Intervention | FVC %-pred (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 66.52 | 67.03 | 67.86 | 69.42 | 69.86 | 71.94 | 72.57 | 72.55 | 70.15 |
| Mycophenolate Arm | 66.52 | 66.22 | 68.02 | 68.11 | 68.43 | 69.84 | 70.57 | 70.87 | 69.65 |
The HAQ-DI asks questions related to 8 activity domains (dressing, arising, eating, walking, hygiene, reach, grip, and common daily activities) with the patient's capacity to carry out each activity scored from 0 to 3. Scores across all domains are averaged and a higher score represents greater disability. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 9, 12, 15, 18, 21, and 24
| Intervention | HAQ-DI Total Score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 0.74 | 0.64 | 0.58 | 0.65 | 0.56 | 0.62 | 0.55 | 0.48 | 0.57 |
| Mycophenolate Arm | 0.71 | 0.83 | 0.75 | 0.66 | 0.64 | 0.58 | 0.55 | 0.65 | 0.62 |
The DLCO is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLCO %-predicted represents the DLCO expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The DLCO %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 12, 15, 18, 21, and 24
| Intervention | DLCO %-pred (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 54.05 | 51.92 | 50.87 | 51.55 | 53.12 | 53.62 | 55.9 | 54.26 | 52.90 |
| Mycophenolate Arm | 53.99 | 53.38 | 54.86 | 54.13 | 55.32 | 57.77 | 56.62 | 55.47 | 55.31 |
Skin thickness is quantified using the modified Rodnan measurement method (mRSS), with a scale that ranges from 0 (no skin involvement) to a maximum of 51. The reported skin score is determined by a clinical assessment of skin thickness, which is performed by a trained reader, and represents the sum of individual assessments that are made in each of 17 body areas. Each area is given a score in the range of 0-3 (0 = normal; 1= mild thickness; 2 = moderate; 3 = severe thickness). A higher score represents more severe skin involvement. (NCT00883129)
Timeframe: Measured at baseline and Months 3, 6, 9, 12, 15, 18, 21, and 24
| Intervention | mRSS score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 14.04 | 12.85 | 11.95 | 10.61 | 9.47 | 9.80 | 9.87 | 8.50 | 7.87 |
| Mycophenolate Arm | 15.32 | 16.03 | 14.37 | 14.33 | 12.45 | 12.43 | 11.98 | 11.22 | 11.40 |
The number of participants who remained in the study at the listed time points are reported (NCT00883129)
Timeframe: Continuous assessment from randomization to 24 months
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 73 | 64 | 56 | 51 | 46 | 44 | 42 | 39 | 38 |
| Mycophenolate Arm | 69 | 66 | 58 | 55 | 52 | 52 | 49 | 49 | 49 |
The TLC represents the total volume of air within the lung after taking the deepest breath possible and the TLC %-predicted represents the TLC expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The TLC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 6, 12, 18, and 24
| Intervention | TLC %-pred (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 6 | Month 12 | Month 18 | Month 24 | |
| Cyclophosphamide Arm | 65.49 | 67.39 | 68.25 | 69.63 | 66.97 |
| Mycophenolate Arm | 66.16 | 67.84 | 67.31 | 68.50 | 68.24 |
(NCT00883129)
Timeframe: Measured throughout the 2-year study
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Leukopenia (<2.5x10^3 WBC/microliter) | Neutropenia (<1.0x10^3 neutrophils/microliter) | Anemia (Hgb <10 g/dl) | Thrombocytopenia (<100x10^3 platelets/microliter) | Hematuria (>10 RBC/high power field) | Pneumonia | SAE-Total | SAE-related to treatment | Deaths | |
| Cyclophosphamide Arm | 30 | 7 | 13 | 4 | 2 | 4 | 22 | 7 | 11 |
| Mycophenolate Arm | 4 | 3 | 8 | 0 | 3 | 5 | 27 | 3 | 5 |
Change in breathlessness was assessed using the Transitional Dyspnea Index, which compares current symptoms to those at baseline. Total score ranges from - 9 to + 9. The lower the score, the more deterioration in severity of dyspnea. (NCT00883129)
Timeframe: Measured at Months 6, 12, 18, and 24
| Intervention | Transitional Dyspnea Index Score (Mean) | |||
|---|---|---|---|---|
| Month 6 | Month 12 | Month 18 | Month 24 | |
| Cyclophosphamide Arm | 0.31 | 1.23 | 1.78 | 2.09 |
| Mycophenolate Arm | 0.74 | 1.17 | 0.91 | 1.86 |
Negative change in FVC percent predicted indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52
| Intervention | FVC percent predicted (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521) | -2.376 |
| Placebo | -2.945 |
The mRSS is a validated physical examination method for estimating skin thickness. It correlates with biopsy measures of collagen in the dermis and reflects prognosis and visceral involvement, especially in early disease. It is scored on 0 (normal) to 3+ (severe induration) ordinal scales over 17 body areas, with a maximum score of 51 (higher score means worse situation) and is used to categorize severity of SSc. A decrease in the mean change of mRSS shows mRSS improved. (NCT02283762)
Timeframe: Baseline to week 52
| Intervention | score on a scale (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521) | -2.088 |
| Placebo | -0.769 |
The HAQ-DI is a composite measure from which a 'Standard Disability Index' score can be computed to assess a patient's disability level. Generally, a score of 0-1 represents mild to moderate difficulty, 1-2 moderate to severe disability and 2-3 severe to very severe disability. The HAQ-DI comprises 20 items that assess patient abilities across 8 functional activities: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item is rated on a 4-point scale: 0=Without ANY difficulty, 1=With SOME difficulty, 2=With MUCH difficulty, 3=UNABLE to do. The 8 scores of the 8 sections are summed and divided by 8. In the event that one section is not completed by a subject then the summed score would be divided by 7. The final overall HAQ-DI score ranges from 0 to 3 and positive change indicates worse health-related quality of life (HRQoL). (NCT02283762)
Timeframe: Baseline to week 52
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline | |
| Placebo | 0.693 | 0.127 |
| Riociguat (Adempas, BAY63-2521) | 0.888 | 0.054 |
The patient's global assessments (a self-report) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the patient's global assessments score indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline | |
| Placebo | 3.770 | -0.022 |
| Riociguat (Adempas, BAY63-2521) | 3.933 | 0.689 |
The physician's global assessments (reported by the physician) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the physician's global assessments score indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline | |
| Placebo | 4.016 | -0.745 |
| Riociguat (Adempas, BAY63-2521) | 4.333 | -0.067 |
CRISS forms a composite response index consisting of SSc-related organ involvement and the following five variables: mRSS, FVC percent predicted, physician's and patient's global assessments, and HAQ-DI score (from SHAQ patient-reported outcome). The resulting index is a 2-step process that captures clinically meaningful worsening of internal organ involvement and the core variables that show change. Patients for whom the predicted CRISS probability was ≥ 0.60 were considered improved, while patients for whom the predicted probability was < 0.60 were considered not improved. (NCT02283762)
Timeframe: Week 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| CRISS probability ≥ 0.60 | CRISS probability < 0.60 | |
| Placebo | 11 | 50 |
| Riociguat (Adempas, BAY63-2521) | 11 | 49 |
2 reviews available for carbon monoxide and Sclerosis, Systemic
| Article | Year |
|---|---|
Predictors of progression in systemic sclerosis patients with interstitial lung disease.
Topics: Biomarkers; Carbon Monoxide; Disease Progression; Humans; Lung; Lung Diseases, Interstitial; Respira | 2020 |
Hydrogen Sulfide: A Therapeutic Option in Systemic Sclerosis.
Topics: Animals; Carbon Monoxide; Humans; Hydrogen Sulfide; Models, Biological; Nitric Oxide; Scleroderma, S | 2018 |
9 trials available for carbon monoxide and Sclerosis, Systemic
| Article | Year |
|---|---|
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Topics: Adult; Carbon Monoxide; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; | 2019 |
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate | 2016 |
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate | 2016 |
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate | 2016 |
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate | 2016 |
RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
Topics: Carbon Monoxide; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Activators; Female; H | 2017 |
High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Topics: Adult; Carbon Monoxide; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Glucocorticoids; | 2009 |
Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis.
Topics: Administration, Oral; Adult; Aged; Carbon Monoxide; Epoprostenol; Female; Humans; Lung; Male; Middle | 2002 |
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Topics: Carbon Monoxide; Double-Blind Method; Dyspnea; Female; Health Status; Humans; Lung Diseases; Male; M | 2005 |
Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy.
Topics: Adult; Aged; Carbon Monoxide; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Immuno | 2006 |
Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
Topics: Administration, Oral; Breath Tests; Carbon Monoxide; Cyclophosphamide; Drug Therapy, Combination; Fe | 2007 |
Failure of vasoldilator infusion to alter pulmonary diffusing capacity in systemic sclerosis.
Topics: Adult; Aged; Carbon Monoxide; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Iloprost | 1991 |
60 other studies available for carbon monoxide and Sclerosis, Systemic
| Article | Year |
|---|---|
Audiological involvement in patients with systemic sclerosis.
Topics: Audiometry; Carbon Monoxide; Hearing Loss; Humans; Otoacoustic Emissions, Spontaneous; Scleroderma, | 2022 |
Utility of the breath-holding test in patients with systemic sclerosis.
Topics: Biomarkers; Carbon Monoxide; Dyspnea; Humans; Reproducibility of Results; Scleroderma, Systemic; Str | 2022 |
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients.
Topics: Biomarkers; Carbon Monoxide; Humans; Hypertension, Pulmonary; Pulmonary Fibrosis; Scleroderma, Syste | 2022 |
Anti-vinculin antibodies as a novel biomarker in Egyptian patients with systemic sclerosis.
Topics: Autoantibodies; Biomarkers; Carbon Monoxide; Egypt; Female; Humans; Lung Diseases, Interstitial; Mal | 2022 |
Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark Analysis.
Topics: Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung; Male; Scleroderma, Systemic; Vital C | 2023 |
Serum microRNAs in Systemic Sclerosis, Associations with Digital Vasculopathy and Lung Involvement.
Topics: Biomarkers; Carbon Monoxide; Humans; Lung; MicroRNAs; Scleroderma, Diffuse; Scleroderma, Systemic; T | 2022 |
Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study.
Topics: Carbon Monoxide; Humans; Iloprost; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic | 2022 |
Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study.
Topics: Carbon Monoxide; Humans; Iloprost; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic | 2022 |
Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study.
Topics: Carbon Monoxide; Humans; Iloprost; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic | 2022 |
Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study.
Topics: Carbon Monoxide; Humans; Iloprost; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic | 2022 |
Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study.
Topics: Carbon Monoxide; Humans; Iloprost; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic | 2022 |
Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study.
Topics: Carbon Monoxide; Humans; Iloprost; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic | 2022 |
Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study.
Topics: Carbon Monoxide; Humans; Iloprost; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic | 2022 |
Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study.
Topics: Carbon Monoxide; Humans; Iloprost; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic | 2022 |
Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study.
Topics: Carbon Monoxide; Humans; Iloprost; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic | 2022 |
Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.
Topics: Adult; Age Distribution; Age Factors; Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Carbon Monox | 2019 |
Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis.
Topics: Aged; Algorithms; Breath Tests; Carbon Monoxide; Cardiac Catheterization; Echocardiography, Doppler; | 2020 |
Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis.
Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; | 2020 |
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.
Topics: Adult; Aged; C-Reactive Protein; Carbon Monoxide; Case-Control Studies; Cross-Sectional Studies; Cyc | 2021 |
Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbon Monoxide; Cyclophosphamide; Diffusion; Echocardio | 2017 |
Combined measurement of carbon monoxide and nitric oxide lung transfer does not improve the identification of pulmonary hypertension in systemic sclerosis.
Topics: Adult; Blood-Air Barrier; Capillary Permeability; Carbon Monoxide; Early Diagnosis; Early Medical In | 2017 |
Environmental Pollution by Benzene and PM
Topics: Adult; Aged; Air Pollutants; Air Pollution; Benzene; Carbon Monoxide; Environmental Monitoring; Fema | 2017 |
Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
Topics: Aged; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Lung; Lung Diseases, Interstitial; | 2018 |
Nailfold Videocapillaroscopy Changes Are Associated With the Presence and Severity of Systemic Sclerosis-Related Interstitial Lung Disease.
Topics: Adult; Aged; Capillaries; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Micros | 2019 |
Long-term effects of immunosuppressive therapy on lung function in scleroderma patients.
Topics: Adult; Carbon Monoxide; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Lung; Male; Midd | 2018 |
Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?
Topics: Aged; Carbon Monoxide; Case-Control Studies; Echocardiography; Female; Humans; Hypertension, Pulmona | 2018 |
Of the need to reconcile discrepancies between two different reference equations for combined single-breath
Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Male; Mathematical Concepts; Middle Aged; Nitric Oxide | 2019 |
Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis.
Topics: Aged; Algorithms; Arterial Pressure; Carbon Monoxide; Cross-Sectional Studies; Female; Humans; Hyper | 2019 |
Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis.
Topics: Aged; Carbon Monoxide; Cohort Studies; Female; Humans; Hypertension, Pulmonary; Lung; Lung Diseases, | 2013 |
Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease.
Topics: Aged; Area Under Curve; Carbon Monoxide; Exercise Test; Female; Forced Expiratory Volume; Humans; Lu | 2014 |
Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung Disea | 2013 |
Pro- and antiangiogenic markers in patients with pulmonary complications of systemic scleroderma.
Topics: Adult; Aged; Biomarkers; Blood Pressure; Carbon Monoxide; Enzyme-Linked Immunosorbent Assay; Eye Pro | 2015 |
Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications.
Topics: Adult; Aged; Autoantibodies; Capillaries; Carbon Monoxide; Diffusion; Female; Fingers; Follow-Up Stu | 2015 |
The frequency of pulmonary hypertension in patients with juvenile scleroderma.
Topics: Adolescent; Age of Onset; Arterial Pressure; Carbon Monoxide; Child; Child, Preschool; Echocardiogra | 2015 |
Diffusing Pulmonary Capacity Measured During Effort: A Possible Early Marker of Pulmonary Involvement In Systemic Sclerosis.
Topics: Biomarkers; Carbon Monoxide; Case-Control Studies; Exercise Test; Female; Humans; Lung Diseases, Int | 2015 |
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
Topics: Adult; Aged; Antibodies, Antinuclear; Autoantibodies; Biomarkers; Carbon Monoxide; Female; Follow-Up | 2015 |
Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4?
Topics: Adult; Bilirubin; Carbon Monoxide; Case-Control Studies; Cytokines; Dendritic Cells; Female; Fibrobl | 2016 |
Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients.
Topics: Carbon Monoxide; Case-Control Studies; Cohort Studies; Diffusion; Female; Humans; Male; Middle Aged; | 2016 |
Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes.
Topics: Adult; Aged; Aged, 80 and over; Aging; Apoptosis; Carbon Monoxide; CD4 Lymphocyte Count; Cell Prolif | 2010 |
Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult.
Topics: Adult; Aged; Blood Pressure; Carbon Monoxide; Case-Control Studies; Female; Humans; Hypertension, Pu | 2011 |
Evaluation of the functional parameters in scleroderma cases with pulmonary involvement.
Topics: Blood Gas Analysis; Carbon Monoxide; Echocardiography; Exercise Tolerance; Female; Humans; Lung Dise | 2010 |
Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Biomarkers; Blood Sedimentation; Cap | 2011 |
Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
Topics: Adult; Aged; Antibodies, Antinuclear; Blood Pressure; Carbon Monoxide; Comorbidity; Cross-Sectional | 2011 |
Impaired carbon monoxide diffusing capacity as a marker of limited systemic sclerosis.
Topics: Adult; Aged; Biomarkers; Carbon Monoxide; Diagnosis, Differential; Diffusion; Female; Follow-Up Stud | 2011 |
Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide.
Topics: Adult; Aged; Blood Volume; Breath Tests; Capillaries; Carbon Monoxide; Case-Control Studies; Female; | 2012 |
The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis.
Topics: Adult; Aged; Carbon Monoxide; Case-Control Studies; Female; Genetic Predisposition to Disease; Genot | 2012 |
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
Topics: Adult; Autoantibodies; Carbon Monoxide; Case-Control Studies; Centromere; Diffusion; Echocardiograph | 2003 |
[BEHAVIOR OF CARBON MONOXIDE DIFFUSION IN CASES OF RHEUMATOID ARTHRITIS, SCLERODERMA SYSTEMIC ERYTHEMATOSUS AND DERMATOMYOSITIS].
Topics: Arthritis; Arthritis, Rheumatoid; Carbon Monoxide; Dermatomyositis; Humans; Lupus Erythematosus, Sys | 1965 |
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis.
Topics: Aged; Blood Pressure; Carbon Monoxide; Cardiac Catheterization; Humans; Hypertension, Pulmonary; Mas | 2004 |
Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001.
Topics: Age Factors; Blood Pressure; Calcitonin Gene-Related Peptide; Carbon Monoxide; Echocardiography, Dop | 2005 |
Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.
Topics: Adult; Aged; Biomarkers; Carbon Monoxide; Dinoprost; Female; Humans; Male; Middle Aged; Oxidative St | 2006 |
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide.
Topics: Aged; Carbon Monoxide; Echocardiography; Female; Fibrosis; Humans; Lung Diseases; Lung Diseases, Int | 2007 |
The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.
Topics: Adult; Biomarkers; Blood Pressure; Carbon Monoxide; Case-Control Studies; Female; Humans; Male; Midd | 2008 |
[Lung involvement in systemic sclerosis].
Topics: Adolescent; Adult; Aged; Biomarkers; Carbon Monoxide; Child; DNA Topoisomerases, Type I; Female; Hum | 2007 |
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
Topics: Adult; Aged; Biomarkers; Capillaries; Carbon Monoxide; Comorbidity; Diffusion; Disease Progression; | 2008 |
Cytokine concentrations in exhaled breath condensates in systemic sclerosis.
Topics: Adult; Aged; Biomarkers; Breath Tests; Carbon Monoxide; Case-Control Studies; Cytokines; Exhalation; | 2008 |
[Disturbances in diffusion in chronic pulmonary diseases (Carbon monoxide method)].
Topics: Adolescent; Adult; Aged; Carbon Monoxide; Female; Humans; Lung Diseases; Male; Middle Aged; Pulmonar | 1967 |
Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis.
Topics: Actuarial Analysis; Adult; Aged; Carbon Monoxide; Female; Follow-Up Studies; Forced Expiratory Volum | 1984 |
Early pulmonary disease in systemic sclerosis: a comparison between carbon monoxide transfer factor and static lung compliance.
Topics: Acute-Phase Proteins; Carbon Monoxide; Humans; Lung Compliance; Lung Diseases; Pulmonary Alveoli; Pu | 1993 |
Increase of pulmonary diffusing capacity in systemic sclerosis.
Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Male; Middle Aged; Pulmonary Diffusing Capacity; Pulmo | 1994 |
Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography.
Topics: Carbon Monoxide; Female; Humans; Male; Middle Aged; Oxygen; Partial Pressure; Pulmonary Diffusing Ca | 1997 |
Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis.
Topics: Biopsy; Bronchoalveolar Lavage; Carbon Monoxide; Cyclophosphamide; Female; Follow-Up Studies; Humans | 2000 |
Single-breath pulmonary diffusing capacity. Reference values and application in connective tissue diseases and in various lung diseases.
Topics: Adult; Aged; Arthritis, Rheumatoid; Biopsy, Needle; Carbon Monoxide; Collagen Diseases; Female; Hemo | 1976 |
Significance of plasma endothelin-1 levels in patients with systemic sclerosis.
Topics: Adult; Aged; Autoantibodies; Carbon Monoxide; Endothelins; Enzyme-Linked Immunosorbent Assay; Female | 1992 |
Isolated diffusing capacity reduction in systemic sclerosis.
Topics: Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Middle Aged; Predictive Value of Tests; Pr | 1992 |
Diffusing capacity of the lung and nifedipine in systemic sclerosis.
Topics: Adult; Carbon Monoxide; Drug Administration Schedule; Female; Hemodynamics; Humans; Lung Diseases; M | 1990 |
D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study.
Topics: Carbon Monoxide; Diffusion; Follow-Up Studies; Humans; Lung; Penicillamine; Pulmonary Fibrosis; Resp | 1987 |
Serial changes in scleroderma and idiopathic interstitial lung disease.
Topics: Adult; Aged; Arteries; Carbon Monoxide; Cyclophosphamide; Female; Humans; Lung Compliance; Male; Mer | 1973 |